Zobrazeno 1 - 10
of 52
pro vyhledávání: ''
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Zsuzsanna Varga, Thomas Ruhstaller, Ulrike Perriard, Dirk Klingbiel, Tilman T. Rau, Jean-Christophe Tille, Beat Thuerlimann, Hanne Hawle, Qiyu Li, Wolfram Jochum
Publikováno v:
Varga, Zsuzsanna; Li, Qiyu; Jochum, Wolfram; Perriard, Ulrike; Rau, Tilman; Tille, Jean-Christoph; Hawle, Hanne; Klingbiel, Dirk; Thuerlimann, Beat; Ruhstaller, Thomas (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific reports, 9(1), p. 13534. Springer Nature 10.1038/s41598-019-49638-4
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ed0eb6c511bb431eb561f8c240921
Autor:
I.A.M. Mandjes, Esther H. Lips, Bas B. Koolen, Lennart Mulder, Sjoerd Rodenhuis, Jelle Wesseling, L. Wessels, J. J. de Ronde
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Intrinsic subtypes are widely accepted for the classification of breast cancer. Lacking gene expression data, surrogate classifications based on immunohistochemistry (IHC) have been proposed. A recent St. Gallen consensus meeting recommends to use th
Autor:
Razelle Kurzrock, Maria Schwaederle, Sherri Z. Millis, David Arguello, Zoran Gatalica, Min Yan
Publikováno v:
Cancer Metastasis Reviews
Cancer metastasis reviews, vol 34, iss 1
Cancer metastasis reviews, vol 34, iss 1
Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been reported in other malignancies, previous studies generally focused on one
Autor:
Mark Laible, Päivi Auvinen, Sebastian Eidt, Harri Sihto, Heikki Joensuu, Taina Turpeenniemi-Hujanen, Ugur Sahin, Sirkku Jyrkkiö, Kornelia Schlombs, Ralph M. Wirtz, Stefan Weber, Pirkko-Liisa Kellokumpu-Lehtinen, Sotiris Lakis, Jorma Isola, Päivi Heikkilä
Publikováno v:
Breast Cancer Research and Treatment
The biological subtype of breast cancer influences the selection of systemic therapy. Distinction between luminal A and B cancers depends on consistent assessment of Ki-67, but substantial intra-observer and inter-observer variability exists when imm
Autor:
Wilma L. Lingle, Beiyun Chen, Michael F. Press, Howard M. Stern, Monica M. Reinholz, Mona Shing, Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Soonmyung Paik, Reid G. Meyer, Melanie Finnigan, Marc Buyse, JoAnne Zujewski, Ivonne Villalobos, Dennis J. Slamon, Chungyeul Kim, Anne E. Wiktor
Publikováno v:
Breast Cancer Research and Treatment
A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed o
Autor:
Matthew J. Ellis, Cynthia X. Ma
Publikováno v:
Breast Cancer Research and Treatment
Neoadjuvant chemotherapy trials have consistently reported lower response rates in hormone receptor-positive (HR+) breast cancer when compared with HR− cases. Preoperative endocrine therapy has therefore become a logical alternative and has gained
Autor:
Anna Glajcar, Joanna Szpor, Katarzyna Ewa Tyrak, Joanna Streb, Agnieszka Pacek, Krzysztof Okoń, Florence Chan, Diana Hodorowicz-Zaniewska
Publikováno v:
Virchows Archiv
Mast cells (MCs) are a part of the innate immune system. The MC functions toward cancer are partially based on the release of chymase and tryptase. However, the MC effect on breast cancer is controversial. The aim of our study was to investigate the
Autor:
Ana Lluch Hernandez, José Alejandro Pérez Fidalgo, José Ángel García Sáenz, Jose Ignacio Chacon Lopez-Muniz, Ángel Guerrero Zotano, Eduardo Martínez de Dueñas, María Helena López de Ceballos Reyna, Jaime Ferrer Lozano, Noelia Martínez Jañez, Silvia Antolín Novoa, Amparo Oltra Ferrando, Gustavo Catalan, Salomón Menjón, Ramon Maria Perez Carrion, Eva Carrasco Carrascal, Vicente Carañana Ballerini, Octavio Burgués Gasión, Antonio Antón Torres, Andrés Hernando Capilla, Isabel Blancas Lopez-Barajas, Montserrat Muñoz Mateu, Ana M. Gonzalez-Angulo, Ángela López Rodríguez
Publikováno v:
Breast Cancer Research and Treatment
The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patien
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression